Cincinnati prehospital stroke scale: reproducibility and validity
RU Kothari, A Pancioli, T Liu, T Brott… - Annals of emergency …, 1999 - Elsevier
Study objective: The Cincinnati Prehospital Stroke Scale (CPSS) is a 3-item scale based on
a simplification of the National Institutes of Health (NIH) Stroke Scale. When performed by a …
a simplification of the National Institutes of Health (NIH) Stroke Scale. When performed by a …
[HTML][HTML] Effect of platelet inhibition with cangrelor during PCI on ischemic events
…, DJ Angiolillo, P Généreux, T Liu… - … England Journal of …, 2013 - Mass Medical Soc
Background The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI)
is an important determinant of PCI-related ischemic complications. Cangrelor is a …
is an important determinant of PCI-related ischemic complications. Cangrelor is a …
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial
…, C Ramaiah, M Brtko, L Cannon, C Dyke, T Liu… - Jama, 2012 - jamanetwork.com
Context Thienopyridines are among the most widely prescribed medications, but their use
can be complicated by the unanticipated need for surgery. Despite increased risk of …
can be complicated by the unanticipated need for surgery. Despite increased risk of …
Patients' awareness of stroke signs, symptoms, and risk factors
…, E Jauch, J Broderick, T Brott, J Khoury, T Liu - Stroke, 1997 - Am Heart Assoc
Background and Purpose We sought to determine knowledge at the time of symptom onset
regarding the signs, symptoms, and risk factors of stroke in patients presenting to the …
regarding the signs, symptoms, and risk factors of stroke in patients presenting to the …
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
…, CM Gibson, KW Mahaffey, S Leonardi, T Liu… - The Lancet, 2013 - thelancet.com
Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that
was tested for percutaneous coronary intervention (PCI) in three large, double-blind, …
was tested for percutaneous coronary intervention (PCI) in three large, double-blind, …
Acute stroke: delays to presentation and emergency department evaluation
…, T Brott, L Sauerbeck, J Khoury, T Liu - Annals of emergency …, 1999 - Elsevier
Study objective: To document prehospital and inhospital time intervals from stroke onset to
emergency department evaluation and to identify factors associated with presentation to the …
emergency department evaluation and to identify factors associated with presentation to the …
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of …
…, T Shaburishvili, K Huber, J Prats, T Liu… - Journal of thrombosis …, 2012 - Springer
Cangrelor is an intravenous antagonist of the P2Y 12 receptor characterized by rapid, potent,
predictable, and reversible platelet inhibition. However, cangrelor was not superior to …
predictable, and reversible platelet inhibition. However, cangrelor was not superior to …
Phase I Trial of the Murine Monoclonal Anti-GD2 Antibody 14G2a in Metastatic Melanoma
MN Saleh, MB Khazaeli, RH Wheeler, E Dropcho, T Liu… - Cancer research, 1992 - AACR
In a phase I trial, 12 patients with G D2 antigen-positive metastatic melanoma received the
murine anti-G D2 monoclonal antibody 14G2a. The monoclonal antibody was administered in …
murine anti-G D2 monoclonal antibody 14G2a. The monoclonal antibody was administered in …
Intraperitoneal radioimmunotherapy of ovarian cancer with177Lu-CC49: a phase I/II study
…, G Plott, M Austin, L Kilgore, CD Russell, T Liu… - Gynecologic …, 1997 - Elsevier
Background.Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase
I/II trial of intraperitoneal 177 Lu-CC49 antibody. Methods.Patients had disease confined …
I/II trial of intraperitoneal 177 Lu-CC49 antibody. Methods.Patients had disease confined …
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (clinical trial comparing cangrelor …
Objectives : This study sought to evaluate the clinical impact of intraprocedural stent thrombosis
(IPST), a relatively new endpoint. Background : In the prospective, double-blind, active-…
(IPST), a relatively new endpoint. Background : In the prospective, double-blind, active-…